SCYNEXIS (SCYX) Projected to Post Quarterly Earnings on Wednesday

SCYNEXIS (NASDAQ:SCYX) is anticipated to issue its Q4 2025 results before the market opens on Wednesday, March 11th. Analysts expect the company to announce earnings of $0.29 per share and revenue of $8.10 million for the quarter. Interested persons can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, March 12, 2026 at 9:30 AM ET.

SCYNEXIS Price Performance

SCYNEXIS stock opened at $0.75 on Wednesday. The firm has a market capitalization of $31.55 million, a price-to-earnings ratio of -1.47 and a beta of 1.33. The company’s 50 day simple moving average is $0.71 and its 200 day simple moving average is $0.75. SCYNEXIS has a fifty-two week low of $0.57 and a fifty-two week high of $1.31.

Hedge Funds Weigh In On SCYNEXIS

Large investors have recently added to or reduced their stakes in the company. Goldman Sachs Group Inc. bought a new stake in shares of SCYNEXIS in the fourth quarter valued at about $1,255,000. Geode Capital Management LLC raised its position in SCYNEXIS by 7.1% in the 4th quarter. Geode Capital Management LLC now owns 449,223 shares of the company’s stock valued at $284,000 after buying an additional 29,775 shares during the last quarter. Vanguard Group Inc. lifted its stake in SCYNEXIS by 6.4% in the 3rd quarter. Vanguard Group Inc. now owns 1,762,322 shares of the company’s stock valued at $1,357,000 after acquiring an additional 105,600 shares in the last quarter. Bridgeway Capital Management LLC lifted its stake in SCYNEXIS by 4.2% in the 2nd quarter. Bridgeway Capital Management LLC now owns 368,180 shares of the company’s stock valued at $248,000 after acquiring an additional 14,689 shares in the last quarter. Finally, Jane Street Group LLC acquired a new position in SCYNEXIS during the 2nd quarter worth approximately $27,000. Institutional investors own 54.37% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of SCYNEXIS in a research report on Monday, December 29th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, SCYNEXIS presently has a consensus rating of “Hold” and an average target price of $3.00.

About SCYNEXIS

SCYNEXIS, Inc is a late‐stage biopharmaceutical company focused on developing and commercializing novel anti‐infective therapies. Headquartered in Jersey City, New Jersey, the company’s primary research and development efforts center on combating invasive and chronic fungal infections, an area of high unmet medical need. SCYNEXIS’s scientific platform is built around its proprietary triterpenoid class of antifungals, which are designed to address resistance and safety limitations associated with existing treatments.

The company’s lead product candidate, ibrexafungerp, represents the first oral glucan synthase inhibitor to reach clinical development.